Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
i hear your concerns but i really don't see how a hostile takeover could occur.
Broadfin holds 8,874,992 shares
Camber holds 8,374,846
Prescott holds 3,263,781
Dafna holds 1,486,004
at the time in 2012 Applied Medical (A/M) purchased 3.3m shares @ 1.65. they sold 500,000 shares leaving 2.8M,...based on those numbers i really don't see how A/M could perform a hostile takeover.
here's the press release,..seems like some fuzzy math,....in that CRDC has a Float of 82.7M and Shares Outstanding 89.0M
February 21, 2012
(c) 2012 Dow Jones & Company, Inc.
Applied Medical Corp., a surgical-tool developer that Institutional Venture Partners is compelling to go public, has purchased a 9.1% stake in publicly traded medical-device company Cardica Inc .
Applied Medical (A/M) bought 3.3 million shares of Cardica common stock for $1.65 a share, giving the deal a price tag of $5.4 million. Applied Medical said it paid for the shares from its working capital.
additionally Broadfin, through their recent 13D, is seeking sole voting power.
i could entertain the possibility of a hostile takeover IF A/M had gone with Institutional Venture Partners,..but they have not as of this date. that p/r was in 2012 so if A/M was going to initiate that IPO it would have already occurred.
could you elaborate and explain how a hostile takeover can occur with two hedge funds owning close to 10% of the company with A/M now owning only approximately 4-5% at best.
on another note,...
i hope all goes well for you CIMA in the many aspects of your life !!!
I really hope this is good news for you! I don't currently hold a position in CRDC. My money is tied up in medical expenses for my son and other investments right now. I'm working on finding some liquidity to purchase a position though.
What concerns me is the potential for a hostile takeover. I don't know if you are aware or not, but Applied Medical holds approximately, a 4.98% stake in CRDC. Originally Applied Medical's stake was 9.10%. After some dilution Applied Medical's stake became approximately 5.20% and Applied Medical sold just enough shares (200,000) to fly under the radar (speculation; so they no longer have to file a SC 13D). Trust me Applied Medical did not need to sell shares. Just the real estate they own is in the hundreds of millions.
Applied Medical is very aggressive and a privately owned company, not to mention the market leader for laparoscopic and other surgical devices.
In my opinion this could turn out very well for those invested or in the worst case scenario a wash with pending litigation due to a hostile takeover where investors were not paid fairly.
I just hope I'm able to obtain a position before the stock starts to move. I have a strong feeling that I have this one by the balls along with their partners.
"I've known for too long lol",...
with all due respect,...the fact that you and i know means squat !
i'm not talking about individuals. i stated "Wall Street."
i (i am a CRDC shareholder) you (if you are a CRDC shareholder) won't move the share price up,...
the big boys will when they start to snap up shares and bring the price back up to $1+ level.
that's the fact.
another fact is,..Kevin Kotler having a 9.98% stake in CRDC and creating a BoD that will potentially move this share price to create interest in the company as a potential buyout candidate from the likes of Johnson&Johnson (J&J has a 12mm surgical cutter) or Covidien (an international company).
with FDA clearance of their 5mm CRDC could potentially become a sector leader.
the best we can perform as a forum is to maintain the most up-to-date company information for potential investors to educate themselves that CRDC is better than a 50/50 r/r,...with the reward side a stronger potential.
make it a good day.
I've known for too long lol
reading through the recent filing held some diamonds shining,...
Item 4.
Purpose of Transaction.
The Reporting Persons purchased the Shares based on the Reporting Persons’ belief that the Shares, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable.
Last year, Broadfin Master and its affiliates (“Broadfin”) led a successful campaign for the election of Gregory D. Casciaro, R. Michael Kleine and Samuel E. Navarro to the Board at the Issuer’s 2014 annual meeting of stockholders.
Despite the valuable contribution of Messrs. Casciaro, Kleine and Navarro, a year later, the Board has failed to enact the real and positive changes that the Issuer’s stockholders demanded through their overwhelming support for the election of Broadfin’s candidates. Broadfin believes that the change of a minority on the Board has proven insufficient to maximize the competitive advantage of the Issuer’s valuable technology and drive meaningful value-creation for the benefit of stockholders.
Accordingly, on September 4, 2015, Broadfin delivered a letter to the Issuer nominating Thomas A. Afzal, Richard M. Ferrari, ***Kevin Kotler, Paul Molloy, and Jeffrey A. Templer and re-nominating Messrs. Casciaro, Kleine and Navarro (together, the “Nominees”) for election to the Board at the 2015 annual meeting of stockholders (the “2015 Annual Meeting”).
***Kevin Kotler is Broadfin's CEO. so CRDC will have a hedge fund manager on th BoD.
AND,...
(b) By virtue of their respective positions with Broadfin Master, each of Broadfin LP, Broadfin Offshore, Broadfin Advisors, Broadfin Capital and Mr. Kotler may be deemed to have sole power to vote and dispose of the Shares reported owned by Broadfin Master.
talk about a captain in charge of the CRDC ship !
Kevin Kotler is taking charge of his investment. Hausen is out and anew CEO is arriving.
Broadfin just uped its holdings,....9.98% of CRDC.
based on this 'vote of confidence' i also uped my holdings. Kolter is there to protect his investment in my point of view,...if he's watching over his 8+M shares,...i'm very confident in my investment.
here are the most recent figures;
CRDC is in a share class of common stock
Float 82.7M
Shares Outstanding 89.0M
Institutions Holding Shares 31%
Held by Institutions 54.61%
additionally on August 25, 2014 Camber Capital Management revealed they now own 8.37M shares of CRDC.
that's close to 10% B/O/,..looking good here.
CRDC is flying under the radar,..no one knows except the hedge funds like Broadfin, Camber, ect. Wall Street has no clue yet.
CRDC,...Kevin Kotler of Broadfin Capital is attempting to get control of board. based on this filing.
via the last c/c Bernard Hausen is out,..the search for a new CEO that can move the company to its new heights,...once FDA clearance is completed,...KABOOM ! (imho)
http://phx.corporate-ir.net/phoenix.zhtml?c=195013&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTEwNDczNzU0JkRTRVE9MCZTRVE9MCZTUURFU0M9U0VDVElPTl9FTlRJUkUmc3Vic2lkPTU3
Is anyone here familiar with the couple of stock acquisitions (5% / 10%) by larger companies? If so, what are your thoughts?
Hello,
I tend to agree with you. I'm new to the stock. Are the any fundamentals that you know of that substantiate the chart?
If someone would bring me up to speed, I would greatly appreciate it. I will continue with my due diligence tomorrow. Let me know if the is anything in particular that we are looking for. I have some ideas of my own. I will share when I have more informantion.
Thank you!
I used to have hope for this dilution hound...I visited this company a few years back. Very random that even the chick at the front desk said they were only good at spending money.
Lots of them have good products but few of them are good stocks lol
also good product/ Cardica, Inc. (CRDC)
0.4295 ? 0.0065 (1.54%)
Volume: 77,098 @ 12:52:31 PM ET
Bid Ask Day's Range
0.4293 0.4295 0.41 - 0.4295
CRDC Detailed Quote Wiki
thank you,
Cardica, Inc. (CRDC)
0.3801 ? 0.0001 (0.03%)
Volume: 154,020 @ 4:00:00 PM ET
Bid Ask Day's Range
0.37 0.44 0.37 - 0.4
CRDC Detailed Quote Wiki
Yikes up 71% where will they be in 8 years?
STRONG BUY here!
Cardica, Inc. (CRDC)
0.4215 ? -0.0085 (-1.98%)
Volume: 124,039 @ 4:00:00 PM ET
Bid Ask Day's Range
0.4 0.4582 0.42 - 0.45
CRDC Detailed Quote Wiki
LOTS of buying today. I think we are at the inversion point on this one!
Just realized institutional ownership is 50% !
Good loading zone here. It feels GOOD to be one of the 1st on the scene with one of these! : )
CRDC is putting its heart into the heart innovation. The old stint operation used to a pain in the XXX. Things have improved..
procedure/ not through groin/ now go through wrist.
overnite stay only.
WOW . I guess that I'd better than swallowing a can of draino to unclog the arteries
last may,june-2014 i had three stents placed in my heart.
$CRDC at the heart of heart innovations .
Cardica, Inc. (CRDC)
0.425 ? -0.005 (-1.16%)
Volume: 41,263 @ 11:43:31 AM ET
Bid Ask Day's Range
0.425 0.444 0.425 - 0.45
CRDC Detailed Quote Wiki
$CRDC on good list this morning.
http://investorshub.advfn.com/Death-Spiral-and-Ghost-Busters-29759/
$CRDC was nominated for verification of having no floorless toxic debt this morning. Please visit the following link for more information.
http://investorshub.advfn.com/Death-Spiral-and-Ghost-Busters-29759/
I just boardmarked $CRDC.
Yep...bout to go inverted! YeeHaw! Nite
strong suited tonight.
: ) It should be fun! Gn
winner written on this one.
Their cash & equivalents (34M) exceed total costs & expenses by a factor of 2. That should improve as they just went thru a design enhancement on their cutter. The last filing indicates that it can now be used for vascular procedures.
In the world of surgical instrumentation, this is HUGE! The most costly surgeries tend to be vascular related. Revenues should fall in line. IMO this just DOUBLED their revenue potential.
The light is GREEN, from where I am sitting!
: )
thank you for invite. how is their burn rate ?????
SURGERIES INSANELY EXPENSIVE! Lots of revenue for the equipment!
Thinking - MUCH MORE to come here!
CARDICA ANNOUNCES FISCAL 2015 SECOND QUARTER FINANCIAL RESULTS
Form 8K
REDWOOD CITY, Calif. – February 5, 2015 -- Cardica, Inc. (Nasdaq: CRDC) today announced financial results for its fiscal second quarter ended December 31, 2014. Cardica’s management will hold a conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide an update on the company’s business.
“Following the voluntary withdrawal of the MircoCutter XCHANGE® 30 in November, Cardica’s primary focus has been on product improvements that would guarantee safe and effective outcomes in deployments not only within the specified range, but also across the full capable tissue thickness range,” said Bernard A. Hausen, M.D., Ph.D., president and CEO of Cardica. “We have identified the areas requiring improvements and are currently undergoing extensive testing in bench models as well as in live animals. With the improved device, we are now conducting a clinical evaluation, and once we have clear evidence of reliable clinical performance in patients, we intend to return to a commercial launch.”
Fiscal 2015 Second Quarter and Six Months Ended December 31, 2014, Financial Results
Total product sales were approximately $0.6 million for the fiscal 2015 second quarter, compared to $0.8 million for the fiscal 2014 second quarter. Total net revenue was approximately $0.7 million for the fiscal 2015 second quarter, compared to $0.9 million for the fiscal 2014 second quarter.
Cost of product sales was approximately $0.9 million for the fiscal 2015 second quarter, compared to approximately $1.1 million for the fiscal 2014 second quarter. Research and development expenses were approximately $1.8 million for the second quarter of fiscal 2015 compared to approximately $1.7 million for the same period of fiscal 2014. Selling, general and administrative expenses were $3.2 million for the fiscal 2015 second quarter compared to $2.2 million for the same period of fiscal 2014. The increase in selling, general and administrative expenses in fiscal 2015 is due primarily to increases in the sales force, sales and marketing expenses and expenses associated with the company’s proxy solicitation.
The net loss for the fiscal 2015 second quarter was approximately $5.4 million, or $0.06 per share. Net loss for the fiscal 2014 second quarter was approximately $4.2 million, or $0.08 per share.
Total net revenue was approximately $1.7 million for each of the six month periods ended December 31, 2014 and December 31, 2013. Total operating costs and expenses for the six months ended December 31, 2014, were approximately $12.0 million compared to $9.4 million for the six months ended December 31, 2013. Net loss for the six months ended December 31, 2014, was approximately $10.5 million, or $0.12 per share, compared to $7.9 million, or $0.15 per share for the same period of fiscal 2013.
Cash, cash equivalents and investments as of December 31, 2014, were approximately $33.6 million, compared to $38.0 million at September 30, 2014. As of December 31, 2014, there were approximately 89 million shares of common stock outstanding and 191,474 shares of Series A convertible preferred stock outstanding.
Form SC 13G/A right before earnings on Thursday
http://phx.corporate-ir.net/phoenix.zhtml?c=195013&p=IROL-sec
Cardica To Announce Fiscal 2015 Second Quarter Financial Results On Thursday, February 5, 2015
8:00 AM ET 1/22/15 | PR Newswire
Cardica, Inc. (Nasdaq: CRDC) today announced that it will release financial results for its fiscal second quarter ended December 31, 2014, on Thursday, February 5, 2015, after the markets close. Cardica's management will host a conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide an update on the company's business.
Conference Call DetailsTo access the live conference call on February 5, 2015, at 4:30 p.m. Eastern Time via phone, please dial 866-318-8611 from the United States and Canada or 617-399-5130 internationally. The conference ID is 61582374. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately four hours after the call through February 12, 2015, and may be accessed by dialing 888-286-8010 from the United States and Canada or 617-801-6888 internationally. The replay passcode is 17913151.
To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company's website at www.cardica.com. Please connect to the website at least 15 minutes prior to the presentation to allow for any necessary software downloads.
The webcast is also being distributed through the Thomson StreetEvents Network. Institutional investors can access the call via Thomson StreetEvents at www.streetevents.com, a password-protected event management site.
About CardicaCardica designs and manufactures proprietary stapling and anastomotic devices for cardiac and laparoscopic surgical procedures. Cardica's technology portfolio is intended to reduce operating time and facilitate minimally-invasive and robot-assisted surgeries. Cardica's MicroCutter XCHANGE(R) 30, a cartridge-based articulating surgical stapling device with a five-millimeter shaft diameter, is manufactured and cleared for use in a variety of gastrointestinal procedures and appendectomies in the United States, and for a wide range of surgical procedures in Europe. Cardica is developing the Cardica(R) MicroCutter XCHANGE(R) 45, a cartridge-based microcutter device that is being designed with an eight-millimeter shaft to be used in a variety of procedures, including bariatric, colorectal, thoracic and general surgery. The Cardica MicroCutter XCHANGE 45 product requires 510(k) clearance and CE Mark and is not yet commercially available in the U.S. or internationally. In addition, Cardica manufactures and markets its automated anastomosis systems, the C-Port(R) Distal Anastomosis Systems and PAS-Port(R) Proximal Anastomosis System for coronary artery bypass graft (CABG) surgery, and has shipped over 53,000 units throughout the world.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cardica-to-announce-fiscal-2015-second-quarter-financial-results-on-thursday-february-5-2015-300024061.html
SOURCE Cardica, Inc.
YOUNGER WILLIAM H JR filed this Form 4 on 12/15/2014
http://phx.corporate-ir.net/phoenix.zhtml?c=195013&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTk5NTI3NDUmRFNFUT0wJlNFUT0wJlNRREVTQz1TRUNUSU9OX0VOVElSRSZzdWJzaWQ9NTc%3d
Did anyone attend the ASM? If so, can you give us a synopses of what was said? Especially if any of the officesr talked about when the microcutter will be ready. Thanks.
Followers
|
16
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
253
|
Created
|
09/05/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |